NASDAQ
12.05.25 | 21:59
7,910 US-Dollar
+4,91 % +0,370
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Cullinan Therapeutics GAAP EPS of -$0.74 beats by $0.07 | 1 | Seeking Alpha | ||
| Do | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| Do | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Do | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results | 664 | GlobeNewswire (Europe) | Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren's... ► Artikel lesen | |
| 29.04. | Cullinan Therapeutics startet Studie zur Sjögren-Krankheit | 2 | Investing.com Deutsch | ||
| CULLINAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 23.04. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, ... | 1 | GlobeNewswire (USA) | ||
| 16.04. | Cullinan Therapeutics Wins EMA Approval To Launch CLN-978 Trial In Rheumatoid Arthritis | 1 | RTTNews | ||
| 16.04. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid ... | 75 | GlobeNewswire (Europe) | Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025 CLN-978 is also being studied in the U.S., Europe... ► Artikel lesen | |
| 27.02. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results | 124 | GlobeNewswire (Europe) | Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus (SLE) expected in Q4 2025; CLN-978 remains the first and only development-stage CD19 T cell engager in an... ► Artikel lesen | |
| 27.02. | Cullinan Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 27.02. | Cullinan Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 27.02. | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.01. | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.01. | Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have ... | 143 | PR Newswire | TOKYO, PRINCETON, N.J. and CAMBRIDGE, Mass., Jan. 28, 2025 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the... ► Artikel lesen | |
| 14.11.24 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | 237 | GlobeNewswire (Europe) | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| 16.10.24 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus | 122 | GlobeNewswire (Europe) | CLN-978 is the first development stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc.... ► Artikel lesen | |
| 17.09.24 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus | 184 | GlobeNewswire (Europe) | Phase 1 clinical trial is designed to assess the safety, pharmacokinetics and initial clinical activity of CLN-978 for patients with systemic lupus erythematosus The trial will be conducted in multiple... ► Artikel lesen | |
| 14.09.24 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 | 575 | GlobeNewswire (Europe) | Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations... ► Artikel lesen | |
| 01.06.24 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib | 182 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced... ► Artikel lesen | |
| 15.05.24 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results | 369 | GlobeNewswire (Europe) | Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978 development to focus exclusively on autoimmune diseases... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 62,72 | 0,00 % | Tempus AI: Starkes Wachstum - Verluste steigen jedoch weiter an | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das erste Quartal 2025 bekannt gegeben und ein rasantes Wachstum vorgelegt. Tempus AI - Aktie:... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,125 | -0,27 % | SpringWorks Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| VERA THERAPEUTICS | 22,490 | +3,59 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 5, 2025, the Compensation Committee granted inducement awards consisting of non-qualified... ► Artikel lesen | |
| KEROS THERAPEUTICS | 13,740 | +0,66 % | Keros Therapeutics, Inc.: Keros Reinforces Commitment to Maximizing Stockholder Value | Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting "FOR" the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025... ► Artikel lesen | |
| ADMA BIOLOGICS | 20,450 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 5,300 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart elebsiran without or with PEG-IFNa, respectively As previously... ► Artikel lesen | |
| 2SEVENTY BIO | 5,000 | 0,00 % | 2seventy bio, Inc. - 10-Q, Quarterly Report | ||
| RECURSION PHARMACEUTICALS | 4,635 | 0,00 % | Why Recursion Pharmaceuticals Stock Plummeted 24% This Week | ||
| TREVI THERAPEUTICS | 6,700 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 470,00 | 0,00 % | Pre-market Movers: Regencell Bioscience, Bakkt Holdings, Sarepta Therapeutics, Harrow, Inc., InnovAge | HONG KONG (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green Regencell Bioscience Holdings Limited (RGC) is... ► Artikel lesen | |
| COGENT BIOSCIENCES | 5,130 | +6,54 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| DYNE THERAPEUTICS | 12,550 | +10,09 % | Dyne Therapeutics, Inc. Q1 Loss Increases, Misses Estimates | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) revealed Loss for its first quarter that increased from last year and missed the Street estimates.The company's earnings came in at -$115.361... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 2,320 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | DALLAS, May 02, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 25,290 | 0,00 % | Summit Therapeutics Q1 2025 slides: Strong cash position supports advancing Ivonescimab pipeline | ||
| JANUX THERAPEUTICS | 26,030 | +1,84 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform |
CULLINAN THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 7,910 Euro und damit +4,91 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CULLINAN THERAPEUTICS INC finden Sie auf Wallstreet Online.